Somalogic
SomaLogic Raises Full-Year 2023 Guidance on 14 Percent Q3 Core Revenue Growth
The proteomics firm beat Wall Street estimates on the top and bottom lines, though total revenues were down 47 percent due to a royalty payment last year.
The firms' merger agreement, filed with the US Securities and Exchange Commission, contradicts previous messaging on layoffs at Standard BioTools.
Standard BioTools, SomaLogic to Merge
The companies will do business under the name Standard BioTools, which was adopted by Fluidigm in 2022.
SomaLogic Q2 Revenues Jump 45 Percent on Assay Services
Assay services revenues were $16.6 million, up 52 percent from $10.9 million a year ago, while product revenues rose fourfold to $2.9 million from $714,000.
SomaLogic Q1 Revenues Fall 11 Percent but Beat Wall Street Consensus
Six weeks after a management shakeup, the proteomics firm is looking for unspecified "inorganic" opportunities to become profitable.